Sfoglia per AUTORE
BUONADONNA A
Collezione AOU Città della Salute di Torino

  

Items : 14

Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group. in JAMA network open / JAMA Netw Open. 2023 Nov 1;6(11):e2341522. doi: 10.1001/jamanetworkopen.2023.41522.
2023
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Gronchi A; Pantaleo MA; Dei Tos AP; Stacchiotti S; Sbaraglia M; Fiore M; Tolomeo F; Aliberti S; Manessi G; Pennacchioli E; Conforti F; Ligorio F; Merlini A; Mogavero A; Baldi GG; Maccaroni E; Brunello A; Badalamenti G; Vincenzi B; Comandini D; Gasperoni S; Boglione A; Buonadonna A; Carpano S; Bertuzzi A; Nannini M; De Pas TM; Fumagalli E; D'Ambrosio L; et alii...

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO. in Clinical colorectal cancer / Clin Colorectal Cancer. 2022 Sep;21(3):220-228. doi: 10.1016/j.clcc.2022.02.003. Epub 2022 Feb 19.
2022
AOU Città della Salute di Torino

Cupini S; Fanchini L; Zaniboni A; Buonadonna A; Tomasello G; Provenzano L; Spagnoletti A; Daniel F; Bergamo F; Germani MM; Conca V; Boccaccino A; Stellato M; Galletti A; Rossini D; Dell'Aquila E; Carlomagno C; Caponnetto S; Rapisardi S; Santini D;

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21.
2022
AOU Città della Salute di Torino

Schöffski P; Scheipl S; Sbaraglia M; Safwat AA; Sangalli C; Rutkowski P; Reichardt P; Piperno-Neumann S; Piana R; Pantaleo MA; Morosi C; Palmerini E; Montemurro M; Mir O; Miah AB; Messiou C; Merimsky O; Martin-Broto J; Lopez-Pousa A; Leithner A; Legius E; Le Grange F; Le Cesne A; Kopeckova K; Krákorová DA; Kawai A; Kasper B; Jutte P; Jungels C; et alii...

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. in British journal of cancer / Br J Cancer. 2021 Sep;125(6):839-845. doi: 10.1038/s41416-021-01483-x. Epub 2021 Jul 12.
2021
AOU Città della Salute di Torino

Cupini S; Fanchini L; Buonadonna A; Ambrosini M; Zaniboni A; Zucchelli G; Caponnetto S; Borelli B; Tomasello G; Marmorino F; Santini D; Antoniotti C; Rasola C; Lonardi S; Conca V; Rossini D; Moretto R; Masi G; Falcone A; Cremolini C;

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(?). in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2021 Nov;32(11):1348-1365. doi: 10.1016/j.annonc.2021.07.006. Epub 2021 Jul 22.
2021
AOU Città della Salute di Torino

Schöffski P; Scheipl S; Sbaraglia M; Safwat AA; Sangalli C; Reichardt P; Rutkowski P; Piperno-Neumann S; Piana R; Pantaleo MA; Palmerini E; Morosi C; Morland B; Montemurro M; Mir O; Messiou C; Merimsky O; Martin-Broto J; Lopez-Pousa A; Leithner A; Legius E; Le Grange F; Le Cesne A; Kopeckova K; Krákorová DA; Kawai A; Kasper B; Kager L; Jutte P; et alii...

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. in British journal of cancer / Br J Cancer. 2021 Jan;124(1):183-190. doi: 10.1038/s41416-020-01089-9. Epub 2020 Oct 7.
2021
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Falcone A; Latiano TP; Rapisardi S; Ritorto G; Masi G; Buonadonna A; Pietrantonio F; Moretto R; Zaniboni A; Caponnetto S; Ricci V; Germani MM; Lonardi S; Antoniotti C; Bergamo F; Santini D; Ermacora P; Tomasello G; Rossini D;

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.
2018
AO Cuneo
AOU Città della Salute di Torino

Falcone A; Fontanini G; Boni L; Sensi E; Zagonel V; Masi G; Allegrini G; Granetto C; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Ronzoni M; Racca P; Moretto R; Cortesi E; Tomasello G; Lonardi S; Bergamo F; Antoniotti C; Cremolini C; Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; et alii...

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.
2018
AO Cuneo
AOU Città della Salute di Torino

Danesi R; Falcone A; Boni L; Zagonel V; Di Donato S; Buonadonna A; Allegrini G; Ricci V; Racca P; Ronzoni M; Tomasello G; Zaniboni A; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Antoniotti C; Lonardi S; Del Re M; Cremolini C;

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.
2018
AOU Città della Salute di Torino

Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D;

Genetic biomarkers for hepatocellular cancer risk in a caucasian population. in World journal of gastroenterology / World J Gastroenterol. 2017 Sep 28;23(36):6674-6684. doi: 10.3748/wjg.v23.i36.6674.
2017
AOU Città della Salute di Torino

Polesel J; Bignucolo A; Cecchin E; De Mattia E; Roncato R; Lupo F; Crovatto M; Buonadonna A; Tiribelli C; Toffoli G;

UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. in Liver international : official journal of the International Association for the Study of the Liver / Liver Int. 2017 Sep;37(9):1345-1353. doi: 10.1111/liv.13411. Epub 2017 Apr 6.
2017
AOU Città della Salute di Torino

De Mattia E; Cecchin E; Polesel J; Lupo F; Tiribelli C; Crovatto M; Buonadonna A; Toffoli G; De Mattia E; Cecchin E; Polesel J; Lupo F; Tiribelli C; Crovatto M; Buonadonna A; Toffoli G;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. in The New England journal of medicine / N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
2014
AOU Città della Salute di Torino

Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A;